Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature

Figure 2 Changes in anti-A and anti-B titers (IgG + IgM) after transplantation. A: IgG anti-A, no significant changes in plasma exchange, interferon, and mesenchymal stem cell therapy + 1d to + 2700d after transplantation, and antibody levels gradually turned negative after Dara treatment; B: IgM anti-A, no significant changes in plasma exchange, interferon, and mesenchymal stem cell therapy until Dara treatment; C: IgG anti-B, no significant changes in plasma exchange, interferon, and mesenchymal stem cell therapy until Dara treatment; D: IgM anti-B, no significant changes in plasma exchange, interferon, and mesenchymal stem cell therapy + 1d to + 2700d after transplantation, and antibody levels gradually turned negative after Dara treatment. PX: Plasma exchange, INF: Interferon, MNC: Mesenchymal stem cell, Dara: Daratumumab.